Your browser doesn't support javascript.
Long-term immune responses in patients with confirmed novel coronavirus disease-2019: a 9-month prospective cohort study in Shanghai, China.
Gong, Xiaohuan; Cui, Peng; Wu, Huanyu; Pan, Hao; Teng, Zheng; Yuan, Fang; Mao, Shenghua; Kong, Dechuan; Han, Ruobing; Zhao, Xue; Zheng, Yaxu; Xiao, Wenjia; Zhu, Yiyi; Fang, Qiwen; Lin, Sheng; Jin, Bihong; Chu, Ruilin; Jiang, Chenyan; Yu, Xiao; Qiu, Qi; Lu, Yihan; Wang, Weibing; Fu, Chen; Sun, Xiaodong.
  • Gong X; Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
  • Cui P; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Wu H; Ministry of Education Key Laboratory of Public Health Safety, Fudan University, Shanghai, China.
  • Pan H; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Teng Z; Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Yuan F; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Mao S; Department of Microbiology, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Kong D; Department of Microbiology, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Han R; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Zhao X; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Zheng Y; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Xiao W; Department of Microbiology, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Zhu Y; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Fang Q; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Lin S; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Jin B; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Chu R; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Jiang C; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Yu X; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Qiu Q; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Lu Y; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Wang W; Department of Infectious Disease Control and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
  • Fu C; Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China.
  • Sun X; Ministry of Education Key Laboratory of Public Health Safety, Fudan University, Shanghai, China.
BMC Infect Dis ; 22(1): 240, 2022 Mar 10.
Article in English | MEDLINE | ID: covidwho-1736349
ABSTRACT

BACKGROUND:

The duration of antibodies against SARS-CoV-2 in Covid-19 patients remains uncertain. Longitudinal serological studies are needed to prevent disease and transmission of the virus.

METHODS:

In 2020, 414 blood samples were tested, obtained from 157 confirmed Covid-19 patients, in a prospective cohort study in Shanghai.

RESULTS:

The seropositive rate of IgM peaked at 40.5% (17/42) within 1 month after illness onset and then declined. The seropositive rate of IgG was 90.6% (58/64) after 2 months, remained above 85% from 2 to 9 months and was 90.9% (40/44) after 9 months. Generalized estimating equations models suggested that IgM (P < 0.001) but not IgG significantly decreased over time. Age ≥ 40 years (adjusted odds ratio [aOR] 4.531; 95% confidence interval [CI] 1.879-10.932), and cigarette smoking (aOR 0.344; 95% CI 0.124-0.951) were associated with IgG, and age ≥ 40 years (aOR 2.820; 95% CI 1.579-5.036) was associated with IgM. After seroconversion, over 90% and 75.1% of subjects were estimated to remain IgG-positive 220 and 254 days, respectively. Of 1420 self-reported symptoms questionnaires, only 5% reported symptoms 9 months after onset.

CONCLUSIONS:

In patients with a history of natural infection, anti-SARS-CoV-2 IgG is long-lived, being present for at least 9 months after illness onset. The long duration of natural immunity can mitigate and eliminate Covid-19 and the ongoing pandemic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Humans Country/Region as subject: Asia Language: English Journal: BMC Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: S12879-022-07173-0

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Adult / Humans Country/Region as subject: Asia Language: English Journal: BMC Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: S12879-022-07173-0